TWi successfully launches generic Sevelamer Carbonate Tablets in TWi label

November 21, 2019. TWi Pharmaceuticals, Inc. announced the official launch of Sevelamer Carbonate Tablets 800mg (equivalent to Renvela) via its fully owned US subsidiary, TWi Pharmaceuticals USA, Inc.


Sevelamer Carbonate Tablets are indicated for the control of serum phosphorus in adults
with chronic kidney disease (CKD) on dialysis. According to IQVIA data, the total sales of Sevelamer Tablets in the US were approximately US $433 million for the 12 months ended September 2019.


About TWi Pharmaceuticals, Inc.
TWi Pharmaceuticals, Inc. is a leading specialty pharmaceutical company based in Taipei, Taiwan, focusing on the development of high barrier to entry generic prescription products ranging from oral controlled release dosage forms to novel drug delivery systems including the utilization of nanoparticles, transdermal, and polymeric oral delivery systems. Leveraging its internal research and development capabilities, together with operational flexibility, process development, manufacturing and regulatory expertise, TWi Pharmaceuticals concentrates on products and technologies that present significant barriers to entry or offer unparalleled market opportunities in the United States. For more information on TWi Pharmaceuticals and its fully owned US subsidiary, TWi Pharmaceuticals USA, Inc., please visit